Vom CCC unterstützte Publikationen 2022
Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction: A Systemic Review and Meta-analysis
Ostapenko, E., Nixdorf, L., Devyatko, Y., Exner, R., Wimmer, K., & Fitzal, F. (2022). Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction: A Systemic Review and Meta-analysis. Annals of surgical oncology, 10.1245/s10434-022-12567-0. Advance online publication. doi.org/10.1245/s10434-022-12567-0
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer
Krajewski, W., Aumatell, J., Subiela, J. D., Nowak, Ł., Tukiendorf, A., Moschini, M., Basile, G., Poletajew, S., Małkiewicz, B., Giudice, F. D., Maggi, M., Chung, B. I., Cimadamore, A., Galosi, A. B., Fave, R., D'Andrea, D., Shariat, S. F., Hornak, J., Babjuk, M., Chorbińska, J., … European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group (2022). Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. Urologic oncology, S1078-1439(22)00227-7. Advance online publication.
https://doi.org/10.1016/j.urolonc.2022.06.008
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity
Sorce, G., Chierigo, F., Flammia, R. S., Hoeh, B., Hohenhorst, L., Tian, Z., Goyal, J. A., Graefen, M., Terrone, C., Gallucci, M., Chun, F., Saad, F., Shariat, S. F., Montorsi, F., Briganti, A., & Karakiewicz, P. I. (2022). Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. Urologic oncology, 40(8), 380.e19–380.e27. doi.org/10.1016/j.urolonc.2022.03.014
A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery
Pallauf, M., König, F., D'Andrea, D., Laukhtina, E., Mostafaei, H., Motlagh, R. S., Quhal, F., Aydh, A., Yanagisawa, T., Kawada, T., Rajwa, P., Lusuardi, L., Soria, F., Karakiewicz, P. I., Rouprêt, M., Rink, M., Lotan, Y., Margulis, V., Singla, N., Xylinas, E., … Pradere, B. (2022). A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. Frontiers in oncology, 12, 907975. doi.org/10.3389/fonc.2022.907975
Pentafecta after radical cystectomy: a necessary yet insufficient tool to describe surgical excellence
Albisinni, S., Mari, A., Soria, F., Marcq, G., Mertens, L., Laukhtina, E., Aziz, A., Gallioli, A., Pradere, B., & European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group (2022). Pentafecta after radical cystectomy: a necessary yet insufficient tool to describe surgical excellence. Minerva urology and nephrology, 74(4), 482–484. doi.org/10.23736/S2724-6051.22.04947-3
Brief update of the new WHO classification for urothelial carcinoma
Compérat, E., Wasinger, G., Oszwald, A., & Shariat, S. (2022). Brief update of the new WHO classification for urothelial carcinoma. Current opinion in urology, 10.1097/MOU.0000000000001020. Advance online publication. doi.org/10.1097/MOU.0000000000001020
Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder
Laukhtina, E., Pradere, B., Lemberger, U., Karakiewicz, P. I., Fajkovic, H., & Shariat, S. F. (2022). Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. Current opinion in urology, 10.1097/MOU.0000000000001013. Advance online publication. doi.org/10.1097/MOU.0000000000001013
Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
Flammia, R. S., Hoeh, B., Hohenhorst, L., Sorce, G., Chierigo, F., Panunzio, A., Tian, Z., Saad, F., Leonardo, C., Briganti, A., Antonelli, A., Terrone, C., Shariat, S. F., Anceschi, U., Graefen, M., Chun, F., Montorsi, F., Gallucci, M., & Karakiewicz, P. I. (2022). Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. International urology and nephrology, 10.1007/s11255-022-03250-0. Advance online publication. doi.org/10.1007/s11255-022-03250-0
Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer
Laukhtina, E., & Shariat, S. F. (2022). Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. European urology, 82(2), 242–243. doi.org/10.1016/j.eururo.2022.04.010
Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee
Taumberger, N., Joura, E. A., Arbyn, M., Kyrgiou, M., Sehouli, J., & Gultekin, M. (2022). Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, ijgc-2022-003685. Advance online publication. doi.org/10.1136/ijgc-2022-003685
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core
Hoeh, B., Flammia, R. S., Hohenhorst, L., Sorce, G., Chierigo, F., Tian, Z., Saad, F., Gallucci, M., Briganti, A., Terrone, C., Shariat, S. F., Graefen, M., Tilki, D., Kluth, L. A., Mandel, P., Chun, F., & Karakiewicz, P. I. (2022). Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. Urologic oncology, S1078-1439(22)00221-6. Advance online publication. doi.org/10.1016/j.urolonc.2022.06.003
Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters
Reiser, E., Pils, D., Grimm, C., Hoffmann, I., Polterauer, S., Kranawetter, M., & Aust, S. (2022). Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters. Cancers, 14(13), 3210. doi.org/10.3390/cancers14133210
Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population
Pötsch, N., Rainer, E., Clauser, P., Vatteroni, G., Hübner, N., Korn, S., Shariat, S. F., Helbich, T. H., & Baltzer, P. (2022). Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population. European journal of radiology, 154, 110431. Advance online publication. doi.org/10.1016/j.ejrad.2022.110431
Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy
Sari Motlagh, R., Schuettfort, V. M., Mori, K., Katayama, S., Rajwa, P., Aydh, A., Grossmann, N. C., Laukhtina, E., Pradere, B., Mostafai, H., Quhal, F., Abufaraj, M., Lee, R., Karakiewicz, P. I., Lotan, Y., Comprate, E., Moschini, M., Gontero, P., & Shariat, S. F. (2022). Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. International journal of urology : official journal of the Japanese Urological Association, 29(7), 676–683. doi.org/10.1111/iju.14869
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal
Kotsopoulos, J., Lubinski, J., Gronwald, J., Menkiszak, J., McCuaig, J., Metcalfe, K., Foulkes, W. D., Neuhausen, S. L., Sun, S., Karlan, B. Y., Eisen, A., Tung, N., Olopade, O. I., Couch, F. J., Huzarski, T., Senter, L., Bordeleau, L., Singer, C. F., Eng, C., Fruscio, R., … Narod, S. A. (2022). Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 31(7), 1351–1358. doi.org/10.1158/1055-9965.EPI-21-1196
Re: Lymph Node Colonization Induces Tumor-immune Tolerance To Promote Distant Metastasis
Hassler, M. R., & Shariat, S. F. (2022). Re: Lymph Node Colonization Induces Tumor-immune Tolerance To Promote Distant Metastasis. European urology, S0302-2838(22)02471-X. Advance online publication. doi.org/10.1016/j.eururo.2022.06.020
The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations
Del Giudice, F., Flammia, R. S., Pecoraro, M., Moschini, M., D'Andrea, D., Messina, E., Pisciotti, L. M., De Berardinis, E., Sciarra, A., & Panebianco, V. (2022). The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World journal of urology, 40(7), 1617–1628. doi.org/10.1007/s00345-022-03969-6
Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study
Laukhtina, E., Boehm, A., Peyronnet, B., Bravi, C. A., Batista Da Costa, J., Soria, F., D'Andrea, D., Rajwa, P., Quhal, F., Yanagisawa, T., König, F., Mostafaei, H., Enikeev, D., Ingels, A., Verhoest, G., D'Hondt, F., Mottrie, A., Joniau, S., Van Poppel, H., de la Taille, A., … Pradere, B. (2022). Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. World journal of urology, 40(7), 1689–1696. doi.org/10.1007/s00345-022-04025-z
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer
Yanagisawa, T., Kimura, T., Hata, K., Narita, S., Hatakeyama, S., Enei, Y., Atsuta, M., Mori, K., Obayashi, K., Yoshihara, K., Kondo, Y., Oguchi, T., Sadakane, I., Habuchi, T., Ohyama, C., Shariat, S. F., & Egawa, S. (2022). Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. The Prostate, 10.1002/pros.24406. Advance online publication. doi.org/10.1002/pros.24406
Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
Singer, C. F., Jahn, S. W., Rudas, M., Bago-Horvath, Z., Fitzal, F., Abete, L., Moinfar, F., Gnant, M., Filipits, M., & Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2022). Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry. Breast (Edinburgh, Scotland), 64, 127–133. doi.org/10.1016/j.breast.2022.05.003
Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review
Rebhan, K., Wasinger, G., Hassler, M. R., Shariat, S. F., & Compérat, E. M. (2022). Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. Current opinion in urology, 32(4), 358–363. doi.org/10.1097/MOU.0000000000001007
Nonmuscle-invasive bladder cancer, old problems, new insights
Compérat, E., Wasinger, G., Oszwald, A., Pradere, B., & Shariat, S. (2022). Nonmuscle-invasive bladder cancer, old problems, new insights. Current opinion in urology, 32(4), 352–357. doi.org/10.1097/MOU.0000000000000997
Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review
Rebhan, K., Wasinger, G., Hassler, M. R., Shariat, S. F., & Compérat, E. M. (2022). Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. Current opinion in urology, 32(4), 358–363. doi.org/10.1097/MOU.0000000000001007
Nonmuscle-invasive bladder cancer, old problems, new insights
Compérat, E., Wasinger, G., Oszwald, A., Pradere, B., & Shariat, S. (2022). Nonmuscle-invasive bladder cancer, old problems, new insights. Current opinion in urology, 32(4), 352–357. doi.org/10.1097/MOU.0000000000000997
Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update
Vartolomei, M. D., Ferro, M., Roth, B., Teoh, J. Y., Gontero, P., & Shariat, S. F. (2022). Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update. Current opinion in urology, 10.1097/MOU.0000000000001010. Advance online publication. doi.org/10.1097/MOU.0000000000001010
International Alliance of Urolithiasis (IAU) Guideline on Retrograde Intrarenal Surgery
Zeng, G., Traxer, O., Zhong, W., Osther, P., Pearle, M. S., Preminger, G. M., Mazzon, G., Seitz, C., Geavlete, P., Fiori, C., Ghani, K. R., Chew, B. H., Git, K. A., Vicentini, F. C., Papatsoris, A., Brehmer, M., Martinez, J. L., Cheng, J., Cheng, F., Gao, X., … Sarica, K. (2022). International Alliance of Urolithiasis (IAU) Guideline on Retrograde Intrarenal Surgery. BJU international, 10.1111/bju.15836. Advance online publication. doi.org/10.1111/bju.15836
Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program
Kerpel-Fronius, A., Monostori, Z., Kovacs, G., Ostoros, G., Horvath, I., Solymosi, D., Pipek, O., Szatmari, F., Kovacs, A., Markoczy, Z., Rojko, L., Renyi-Vamos, F., Hoetzenecker, K., Bogos, K., Megyesfalvi, Z., & Dome, B. (2022). Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. European radiology, 32(7), 4457–4467. doi.org/10.1007/s00330-022-08589-7
Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis
Lang, C., Egger, F., Alireza Hoda, M., Saeed Querner, A., Ferencz, B., Lungu, V., Szegedi, R., Bogyo, L., Torok, K., Oberndorfer, F., Klikovits, T., Schwendenwein, A., Boettiger, K., Renyi-Vamos, F., Hoetzenecker, K., Schelch, K., Megyesfalvi, Z., & Dome, B. (2022). Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis. Lung cancer (Amsterdam, Netherlands), 169, 40–46. doi.org/10.1016/j.lungcan.2022.05.010
Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
Singer, C. F., Jahn, S. W., Rudas, M., Bago-Horvath, Z., Fitzal, F., Abete, L., Moinfar, F., Gnant, M., Filipits, M., & Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2022). Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry. Breast (Edinburgh, Scotland), 64, 127–133. Advance online publication. doi.org/10.1016/j.breast.2022.05.003
The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study
Bolliger, M., Lanmüller, P., Schuetz, M., Heilig, B., Windischbauer, A., Jakesz, R., Zehetgruber, T., Gnant, M., Gleiss, A., Dörfler, D., Singer, C., Bartsch, R., Haslik, W., Montagna, G., & Fitzal, F. (2022). The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cance - A prospective, controlled, single-center study. International journal of surgery (London, England), 106694. Advance online publication. https://doi.org/10.1016/j.ijsu.2022.106694
Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy
Hoeh, B., Flammia, R. S., Hohenhorst, L., Sorce, G., Panunzio, A., Chierigo, F., Nimer, N., Tian, Z., Saad, F., Gallucci, M., Briganti, A., Shariat, S. F., Graefen, M., Tilki, D., Antonelli, A., Terrone, C., Kluth, L. A., Becker, A., Chun, F., & Karakiewicz, P. I. (2022). Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. Surgical oncology, 42, 101783. doi.org/10.1016/j.suronc.2022.101783
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and ... (EFC) consensus statement on pre-invasive vulvar lesions
Preti, M., Joura, E., Vieira-Baptista, P., Van Beurden, M., Bevilacqua, F., Bleeker, M., Bornstein, J., Carcopino, X., Chargari, C., Cruickshank, M. E., Erzeneoglu, B. E., Gallio, N., Heller, D., Kesic, V., Reich, O., Stockdale, C. K., Esat Temiz, B., Woelber, L., Planchamp, F., Zodzika, J., … Gultekin, M. (2022). The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, ijgc-2021-003262. Advance online publication. doi.org/10.1136/ijgc-2021-003262
Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy
Moretton, A., Slyskova, J., Simaan, M. E., Arasa-Verge, E. A., Meyenberg, M., Cerrón-Infantes, D. A., Unterlass, M. M., & Loizou, J. I. (2022). Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy. Frontiers in oncology, 12, 874201. doi.org/10.3389/fonc.2022.874201
Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis
Kawada, T., Yanagisawa, T., Rajwa, P., Sari Motlagh, R., Mostafaei, H., Quhal, F., Laukhtina, E., Aydh, A., König, F., Pallauf, M., Pradere, B., Ceci, F., Baltzer, P., Hacker, M., Rasul, S., Karakiewicz, P. I., Araki, M., Nasu, Y., & Shariat, S. F. (2022). Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European urology oncology, S2588-9311(22)00064-5. Advance online publication. https://doi.org/10.1016/j.euo.2022.04.006
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Arboleda, B., Bartsch, R., de Azambuja, E., Hamilton, E., Harbeck, N., Klemp, J., Knauer, M., Kuemmel, S., Mahtani, R., Schwartzberg, L., Villarreal-Garza, C., & Wolff, A. (2022). Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. The oncologist, oyac101. Advance online publication. https://doi.org/10.1093/oncolo/oyac101
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer
Afferi, L., Lonati, C., Montorsi, F., Briganti, A., Necchi, A., Mari, A., Minervini, A., Tellini, R., Campi, R., Schulz, G. B., Black, P. C., di Trapani, E., de Cobelli, O., Karnes, R. J., Ahmed, M., Mir, M. C., Algarra, M. A., Rink, M., Zamboni, S., Mondini, F., … European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group (2022). Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. European urology oncology, S2588-9311(22)00062-1. Advance online publication. https://doi.org/10.1016/j.euo.2022.04.001
Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas
Ghilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., Myers, J., Chen, A. I., Schachter, L., Yelton, R., Ballard, H. J., Hodges Dwinal, A., Gier, S., Victoriano, D., Weber, E., Napier, E., … Schuster, S. J. (2022). Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, S0923-7534(22)01722-7. Advance online publication. doi.org/10.1016/j.annonc.2022.05.521
Neoadjuvant Immunotherapy in Gastrointestinal Cancers - The New Standard of Care?
Petricevic, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. (2022). Neoadjuvant Immunotherapy in Gastrointestinal Cancers - The New Standard of Care?. Seminars in cancer biology, S1044-579X(22)00126-2. Advance online publication. https://doi.org/10.1016/j.semcancer.2022.05.015
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score
de Winter, M. A., Dorresteijn, J., Ageno, W., Ay, C., Beyer-Westendorf, J., Coppens, M., Klok, F. A., Moustafa, F., Riva, N., Ruiz Artacho, P. C., Vanassche, T., & Nijkeuter, M. (2022). Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. Thrombosis and haemostasis, 122(5), 818–829. doi.org/10.1055/s-0041-1735251
Unanswered questions in cancer-associated thrombosis
Sanfilippo, K. M., Moik, F., Candeloro, M., Ay, C., Di Nisio, M., & Lee, A. (2022). Unanswered questions in cancer-associated thrombosis. British journal of haematology, 10.1111/bjh.18276. Advance online publication. https://doi.org/10.1111/bjh.18276
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Gampenrieder, S. P., Pircher, M., Fesl, C., Rinnerthaler, G., Mlineritsch, B., Greil-Ressler, S., Steger, G. G., Sagaster, V., Fitzal, F., Exner, R., Devyatko, Y., Balic, M., Stöger, H., Suppan, C., Bauernhofer, T., Singer, C. F., Pfeiler, G., Seifert, M., Helfgott, R., Heck, D., … Greil, R. (2022). Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Breast care (Basel, Switzerland), 17(2), 137–145. doi.org/10.1159/000516157
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.
Taghizadeh H, Maj-Hes A, Prager GW, Müllauer L, Mader RM. Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors. Cancers (Basel). 2022 Apr 12;14(8):1936. doi.org/10.3390/cancers14081936 PMID: 35454843; PMCID: PMC9032789.
Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
Sinn, K., Mosleh, B., Steindl, A., Zoechbauer-Mueller, S., Dieckmann, K., Widder, J. ,Steiner, E., Klepetko, W., Hoetzenecker, K., Laszlo, V., Doeme, B., Klikovits, T., & Hoda, M. A. (2022). Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study. ESMO open, 7(2), 100466. https://doi.org/10.1016/j.esmoop.2022.100466